Spero Therapeutics (SPRO) Cash from Operations (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Cash from Operations came in at 15864000.0 in Q1 2026, up 496.4% YoY from 2659951.73 in Q1 2025, and up 289.97% on a QoQ basis from 8351000.0 in Q4 2025.
Spero Therapeutics (SPRO) Cash from Operations (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Cash from Operations data on file, last reported at 15864000.0 in Q1 2026.
- Quarterly Cash from Operations rose 496.4% year-over-year to 15864000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7242000.0 (up 121.69% YoY) and the FY2025 annual result came in at 12624000.0, up 46.15% from the prior year.
- Cash from Operations improved to 15864000.0 in Q1 2026, from 8351000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 44482000.0 in Q4 2022 to a low of 28223000.0 in Q1 2022.
- A 5-year average of 3584117.65 and a median of 8351000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 1763.01% — and 2025, when it tumbled 167.4%.
- Tracing SPRO's Cash from Operations over 5 years: stood at 44482000.0 in 2022, then sank by 139.33% to 17493000.0 in 2023, then plunged by 33.77% to 23401000.0 in 2024, then surged by 64.31% to 8351000.0 in 2025, then soared by 289.97% to 15864000.0 in 2026.
- The last three Cash from Operations figures came in at 15864000.0 (Q1 2026), 8351000.0 (Q4 2025), and 17422000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 728.46 Mn |
| 10 | Spero Therapeutics | 71.30 Mn | 20.53 Mn | - | -5.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.36 Mn |
| Jun 30, 2026 | -5.36 Mn |
| Mar 31, 2026 | 15.86 Mn |
| Mar 31, 2026 | 15.86 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Sep 30, 2025 | 17.42 Mn |
| Sep 30, 2025 | 17.42 Mn |
| Jun 30, 2025 | -17.69 Mn |
| Jun 30, 2025 | -17.69 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Dec 31, 2024 | -23.40 Mn |
| Dec 31, 2024 | -23.40 Mn |
| Sep 30, 2024 | 12.76 Mn |
| Sep 30, 2024 | 12.76 Mn |
| Jun 30, 2024 | -18.74 Mn |
| Jun 30, 2024 | -18.74 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Mar 31, 2024 | 5.94 Mn |